Apyx Medical Corporation (APYX) News
Filter APYX News Items
APYX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
APYX News Highlights
- For APYX, its 30 day story count is now at 5.
- Over the past 21 days, the trend for APYX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
Latest APYX News From Around the Web
Below are the latest news stories about Apyx Medical Corp that investors may wish to consider to help them evaluate APYX as an investment opportunity.
Apyx Medical Submits Additional FDA 510(k) For Expanded Use Of Renuvion In Dermatological ProceduresApyx Medical Corporation (NASDAQ: APYX) announced the publication of an article in a journal featuring the results of its U.S. IDE study evaluating the Renuvion Dermal Handpiece using Apyx's Helium Plasma Technology for dermal resurfacing procedures. The Company has also submitted a 510(k) premarket notification to the FDA. The primary efficacy endpoint was achieved, with 100% of the study's subjects achieving a more than a 1-point improvement on the Fitzpatrick Wrinkle and Elastosis Scale (FWS) |
Apyx Medical Corporation Announces Peer-Reviewed Publication Featuring Results from the U.S. IDE Clinical Study Evaluating the Renuvion® Dermal Handpiece Using Apyx’s Helium Plasma Technology for Dermal Resurfacing ProceduresCLEARWATER, Fla., February 17, 2022--Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a maker of medical devices, and supplier and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced the publication of a peer-reviewed article in the journal, Lasers in Surgery and Medicine, the official journal of the American Society for Laser Medicine & Surgery, featuring the results of its |
A Look At The Intrinsic Value Of Apyx Medical Corporation (NASDAQ:APYX)Today we will run through one way of estimating the intrinsic value of Apyx Medical Corporation ( NASDAQ:APYX ) by... |
InMode: Initiates Coverage With Hold Rating Prior To FY21 Earnings ReleaseOn February 10, 2022, Israel-based InMode (NASDAQ:INMD) will report its financial results for FY21. While the company published preliminary results on January 12, 2022, a couple of data points still need additional color. In this analysis, Arenberg Capital provides a brief general overview of the company, what items to look... |
Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2021 Financial Results on March 17, 2022CLEARWATER, Fla., January 27, 2022--Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that financial results for the fourth quarter and fiscal year 2021 will be released before the market opens on Thursday, March 17th. |
Medtronic (MDT) Undertakes Investment to Advance STEM EducationThe Medtronic Foundation, solely funded by Medtronic plc (MDT), entered into 13 new partnerships to bridge the inequity in STEM education among underrepresented and underserved communities. |
Ensign Group (ENSG) Up 7.4% in 3 Months: More Growth Ahead?Ensign Group (ENSG) is likely to keep growing on the back of Skilled services and impressive financial strength. |
Molina Healthcare (MOH) Up 14.4% in 6 Months: Growth Ahead?Molina Healthcare (MOH) is likely to keep growing on the back of increasing membership and higher premium revenues. |
Select Medical (SEM) '21 Sales View Up, Labor Costs Ail ProfitsSelect Medical Holdings (SEM) estimates net operating revenues for 2021 to be $6.2 billion, up from the previous expectations. |
Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2021 Revenue ResultsCLEARWATER, Fla., January 10, 2022--Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2021. |